Not a single study
Story checked
Subcutaneous tarlatamab exhibits low toxicity rates in phase 1b trial (opens in a new tab)
news-medical.net · 2026-09-12
Short answer
Not a single studyNo clear answer.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Subcutaneous tarlatamab exhibits low toxicity rates in phase 1b trial
news-medical.net · 2026-09-12
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
This story isn't reporting one study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Open claim evidenceSearch result
No single source study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 5Not checkedSubcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer, according to the phase 1b DeLLphi-308 study.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 5Not checkedThe study was the first to investigate subcutaneous delivery of tarlatamab, which may improve convenience and produce delayed lower peak serum concentrations than intravenous administration, potentially affecting the incidence or severity of adverse events such as cytokine release syndrome.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 5Not checkedPedro Rocha said that 15 mg subcutaneous tarlatamab can achieve serum exposures comparable to the approved 10 mg intravenous dosing given every two weeks while maintaining a favorable safety profile.View evidenceHide evidence
As stated15 mg subcutaneous; 10 mg intravenous every two weeks
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 5Not checkedAs of March 5, 2026, 40 patients had received the 15 mg target dose; treatment-related adverse events occurred in 85% of patients, 10% had grade 3 or higher treatment-related adverse events, no grade 5 treatment-related adverse events occurred, and no grade 3 or higher cytokine release syndrome was reported.View evidenceHide evidence
As stated40 patients; 85% TRAEs; 10% grade ≥3 TRAEs; no grade 5 TRAEs; no grade ≥3 CRS
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 5Not checkedThe preliminary objective response rate in the 15 mg group was 30%, and investigators concluded that the safety profile, pharmacokinetic findings, and preliminary antitumor activity support further investigation of subcutaneous tarlatamab.View evidenceHide evidence
As stated30% objective response rate
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Crossref, Europe PMC · 15 candidate papers
Systematic review and network meta-analysis: evaluation of systemic therapies for platinum refractory or resistant small cell lung cancer.
Lung Cancer (Amsterdam, Netherlands) · 2025 · PubMed
Managing Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Syndrome Resulting From Tarlatamab
Default Digital Object Group · 2026 · Crossref
Outcomes of Concurrent Radiotherapy With Tarlatamab in Extensive-Stage Small Cell Lung Cancer From the DLL3 PanTUMOR Database.
2026 · Europe PMC
TARLATAMAB: A NEWLY APPROVED TREATMENT FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER AND ITS ASSOCIATION WITH CYTOKINE RELEASE SYNDROME
CHEST · 2025 · Crossref
Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice.
2026 · Europe PMC
And 10 more candidates considered.